BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-874@pharmaconomics
DTSTAMP:20260707T034600Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:NAMS PDUFA — obicetrapib (estimated date)
DESCRIPTION:The FDA's approval decision on obicetrapib for cardiovascular disease is due ~ Jun 30\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/nams-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/874
URL:https://www.pharmaconomics.com/e/874
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NAMS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR